Cargando…

Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors

The usefulness of non-steroidal anti-inflammatory drugs (NSAIDs) is hampered by their gastrointestinal side effects. Non-selective cyclooxygenases inhibitors interfere with both COX-1 and COX-2 isozymes. Since COX-1 mediates cytoprotection of gastric mucosa, its inhibition leads to the undesirable s...

Descripción completa

Detalles Bibliográficos
Autores principales: Badrey, Mohamed G., Abdel-Aziz, Hassan M., Gomha, Sobhi M., Abdalla, Mohamed M., Mayhoub, Abdelrahman S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332013/
https://www.ncbi.nlm.nih.gov/pubmed/26307959
http://dx.doi.org/10.3390/molecules200815287
_version_ 1783387250167382016
author Badrey, Mohamed G.
Abdel-Aziz, Hassan M.
Gomha, Sobhi M.
Abdalla, Mohamed M.
Mayhoub, Abdelrahman S.
author_facet Badrey, Mohamed G.
Abdel-Aziz, Hassan M.
Gomha, Sobhi M.
Abdalla, Mohamed M.
Mayhoub, Abdelrahman S.
author_sort Badrey, Mohamed G.
collection PubMed
description The usefulness of non-steroidal anti-inflammatory drugs (NSAIDs) is hampered by their gastrointestinal side effects. Non-selective cyclooxygenases inhibitors interfere with both COX-1 and COX-2 isozymes. Since COX-1 mediates cytoprotection of gastric mucosa, its inhibition leads to the undesirable side effects. On the other hand, COX-2 is undetectable in normal tissues and selectively induced by inflammatory stimuli. Therefore, it is strongly believed that the therapeutic benefits derive from inhibition of COX-2 only. The presence of a strong connection between reported COX-2 inhibitors and cardiac toxicity encourages medicinal chemists to explore new scaffolds. In the present study, we introduced imidazopyrazolopyridines as new potent and selective COX-2 inhibitors that lack the standard pharmacophoric binding features to hERG. Starting from our lead compound 5a, structure-based drug-design was conducted and more potent analogues were obtained with high COX-2 selectivity and almost full edema protection, in carrageenan-induced edema assay, in case of compound 5e. Increased bulkiness around imidazopyrazolopyridines by adding a substituted phenyl ring(s) afforded less active compounds.
format Online
Article
Text
id pubmed-6332013
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63320132019-01-24 Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors Badrey, Mohamed G. Abdel-Aziz, Hassan M. Gomha, Sobhi M. Abdalla, Mohamed M. Mayhoub, Abdelrahman S. Molecules Article The usefulness of non-steroidal anti-inflammatory drugs (NSAIDs) is hampered by their gastrointestinal side effects. Non-selective cyclooxygenases inhibitors interfere with both COX-1 and COX-2 isozymes. Since COX-1 mediates cytoprotection of gastric mucosa, its inhibition leads to the undesirable side effects. On the other hand, COX-2 is undetectable in normal tissues and selectively induced by inflammatory stimuli. Therefore, it is strongly believed that the therapeutic benefits derive from inhibition of COX-2 only. The presence of a strong connection between reported COX-2 inhibitors and cardiac toxicity encourages medicinal chemists to explore new scaffolds. In the present study, we introduced imidazopyrazolopyridines as new potent and selective COX-2 inhibitors that lack the standard pharmacophoric binding features to hERG. Starting from our lead compound 5a, structure-based drug-design was conducted and more potent analogues were obtained with high COX-2 selectivity and almost full edema protection, in carrageenan-induced edema assay, in case of compound 5e. Increased bulkiness around imidazopyrazolopyridines by adding a substituted phenyl ring(s) afforded less active compounds. MDPI 2015-08-21 /pmc/articles/PMC6332013/ /pubmed/26307959 http://dx.doi.org/10.3390/molecules200815287 Text en © 2015 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Badrey, Mohamed G.
Abdel-Aziz, Hassan M.
Gomha, Sobhi M.
Abdalla, Mohamed M.
Mayhoub, Abdelrahman S.
Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors
title Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors
title_full Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors
title_fullStr Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors
title_full_unstemmed Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors
title_short Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors
title_sort design and synthesis of imidazopyrazolopyridines as novel selective cox-2 inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332013/
https://www.ncbi.nlm.nih.gov/pubmed/26307959
http://dx.doi.org/10.3390/molecules200815287
work_keys_str_mv AT badreymohamedg designandsynthesisofimidazopyrazolopyridinesasnovelselectivecox2inhibitors
AT abdelazizhassanm designandsynthesisofimidazopyrazolopyridinesasnovelselectivecox2inhibitors
AT gomhasobhim designandsynthesisofimidazopyrazolopyridinesasnovelselectivecox2inhibitors
AT abdallamohamedm designandsynthesisofimidazopyrazolopyridinesasnovelselectivecox2inhibitors
AT mayhoubabdelrahmans designandsynthesisofimidazopyrazolopyridinesasnovelselectivecox2inhibitors